XML 9 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2024
Feb. 14, 2025
Jun. 30, 2024
Cover [Abstract]      
Entity Registrant Name INNOVIVA, INC.    
Document Type 10-K/A    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Document Transition Report false    
Entity File Number 000-30319    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 94-3265960    
Entity Address, Address Line One 1350 Old Bayshore Highway, Suite 400    
Entity Address, City or Town Burlingame    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94010    
City Area Code 650    
Local Phone Number 238-9600    
Title of 12(b) Security Common Stock $0.01 Par Value    
Trading Symbol INVA    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 899,110,517
Entity Common Stock, Shares Outstanding   62,675,545  
Entity Central Index Key 0001080014    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Amendment Flag true    
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

 

Specified portions of the registrant’s definitive Proxy Statement to be issued in conjunction with the registrant’s 2025 Annual Meeting of Stockholders, which is expected to be filed not later than 120 days after the registrant’s fiscal year ended December 31, 2024, are incorporated by reference into Part III of this Annual Report. Except as expressly incorporated by reference, the registrant’s Proxy Statement shall not be deemed to be a part of this Annual Report on Form 10-K/A.

    
Auditor Name Deloitte & Touche LLP    
Auditor Location San Jose, CA    
Auditor Firm ID 34    
Amendment Description This Amendment No. 1 on Form 10-K/A (the “Amendment”) amends the Annual Report on Form 10-K of Innoviva, Inc. (the “Company”) for the year ended December 31, 2024, originally filed on February 26, 2025 (the “Original Filing”), is being filed pursuant to and in compliance with the time requirements of Rule 3-09 of Regulation S-X, to amend Item 15, Exhibits and Financial Statement Schedules, to include the Audited Consolidated Financial Statements of Armata Pharmaceuticals, Inc. (“Armata”) at December 31, 2024 and 2023 and for the years then ended and the Consent of Ernst & Young LLP Independent Registered Public Accounting Firm of Armata as Exhibit 99.1 and Exhibit 23.3, respectively. These exhibits were not available at the time of the Original Filing. Additional information on the Audited Consolidated Financial Statements of Armata for the year ended December 31, 2022 can be found in the Company’s Amendment No. 2 on Form 10-K/A for the year ended December 31, 2023, filed on March 22, 2024, and is incorporated herein by reference.